Serum-derived extracellular vesicles inhibit osteoclastogenesis in active-phase patients with SAPHO syndrome.

Yanpan GaoYanyu ChenLun WangXiujuan Hou Wei Ge

Published in: Therapeutic advances in musculoskeletal disease (2021)

In this study, we identified SAA1 as an additional inflammation marker that can potentially assist the diagnosis of SAPHO syndrome, and speculated that Nucleolin is a key regulator of osteoclastogenesis in active-phase patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
case report
prognostic factors
peritoneal dialysis
bone loss
patient reported outcomes
inflammatory response